among postmenopausal women only, those in the highest versus lowest quartile of lignan intakes had a statistically significant reduction in the risk of all cause mortality (hr 0.49, 95% ci 0.26–0.91) and a significantly reduced risk of breast cancer mortality (hr 0.29, 95% ci 0.11–0.76).